One-sentence summary: Via a mechanism that involves targeting Rhes, lonafarnib can induce lysosomal-mediated tau degradation and prevent pathology in a tau mouse model.
Introduction
The tauopathies constitute a broad range of diseases all of which share the hallmark feature of tau inclusions. Although tau-related diseases including Alzheimer's disease and chronic traumatic encephalopathy are serious public health problems (1) , no disease-modifying treatment currently exists for these conditions. Generally, approaches to treatment have directly targeted the tau protein and include tau antibodies (2) , antisense oligonucleotides (3), caspase cleavage products (4) , and anti-aggregation agents (5) ; however, few pharmacologic interventions directed toward tau pathways have reached clinical trials. Interventions in upstream pathways such as tau phosphorylation (6) and acetylation inhibitors (7) have shown some efficacy in animal models; however, none of these approaches has had success in human clinical trials. Rapidly growing interest in autophagy as a downstream pathway that mediates tau clearance (8) as well as the implication of autophagy and lysosomes in other neurodegenerative conditions (9) (10) (11) suggests therapeutic opportunities. One potentially druggable pathway linked to autophagy has been suggested in Huntington's disease (HD). This pathway is mediated by the RASD2 gene, which encodes the Rhes protein, a small GTPase member of the Ras superfamily (12) . RASD2 became of interest in HD because it was thought to be expressed mainly in the striatum (13) ; however, in humans, Rhes expression is clearly evident in the cerebral cortex (14) . Rhes activates autophagy independently of mTOR via interaction with Beclin 1 (15) . Furthermore, Rhes has been shown to modulate the aggregation state of mutant Huntingtin (mHtt) by promoting its sumoylation, thus reducing cell survival (16) . This toxicity involves binding of Rhes to mHtt and requires the Rhes CXXX farnesylated membrane attachment site (16) . We became interested in these findings because the induction of autophagy is considered a pharmacological class effect of farnesyl transferase inhibition (17) and therefore could have broader effects than those mediated by the Rhes pathway alone and be relevant for tauopathies. Therefore we studied farnesyl transferase as a therapeutic target for the treatment of tauopathies and present the use of the farnesyl transferase inhibitor, lonafarnib, a drug with which there is extensive clinical experience (18) (19) (20) , as a proof of concept.
Results

Farnesylation inhibition attenuates tau pathology in rTg4510 mice.
Lonafarnib is a potent farnesyl transferase inhibitor with a Ki in the nM range (21) , crosses the blood brain barrier and has few minor side effects in humans. We sought to determine the effects of lonafarnib administration in the rTg4510 mouse, a widely used model for frontotemporal dementia (22) . These mice were reported to develop tau tangles in the cerebral cortex by 4 months of age and in the hippocampus by 5.5 months. By 5.5 months, the mice also lose about 60% of their hippocampal CA1 neurons (22) . Spatial memory deficits become apparent by 2.5 to 4 months of age; however electrophysiological properties of cortical neurons are affected before the accumulation of tau pathology (23, 24) . To determine precisely the effects of lonafarnib we replicated the time course for the onset of pathology in rTg4510 ( Fig. 1; supplemental Fig. 1 ). Similar to the reported data, MC1 immunoreactivity, corresponding to neurofibrillary tangles throughout hippocampus, amygdala, entorhinal cortex and cerebrocortex ( Fig. 1A ; green), was first detected at ~16 weeks (supplemental Lonafarnib treatment was initiated at ten weeks of age. Lonafarnib was resuspended in 20% 2-Hydroxypropyl)-β-cyclodextrin as vehicle and gavage fed on an intermittent schedule, five days on five days off at 80 mg/Kg/day (25) . The drug was remarkably effective in reducing MC1 immunoreactivity. When evaluated at 20-weeks ( Fig. 2B-H -3 , hippocampus p=6.4x10 -3 ), or untreated age-matched transgenic mice (cortex p=3.5x10 -3 , hippocampus p=2.4x10 -5 ).
In contrast to chronic administration, lonafarnib was ineffective as an acute intervention. For this experiment, animals were gavage-treated daily for 2 weeks (80 mg/Kg/day) in 20 week-old rTg4510 mice, after tau pathology was widespread. This treatment failed to alter the location and the extent of the MC1 pathology observed when compared to age-matched vehicle treated and untreated transgenic mice (data not shown).
Chronic lonafarnib treatment also prevented the reduction in brain size among aged transgenic mice. Coronal section area of littermate controls (Ctr) and transgenic (Tg) mice did not differ at five weeks, but significantly diminished by 20 weeks, as mice aged (Fig. 1B) . Lonafarnib-treated Tg (L80) mice at 20-weeks had significantly larger coronal brain areas than both vehicle (Veh) and Untreated (Unt) age-matched transgenic mice ( Fig. 2A ; ANOVA p=1.32x10 -3 ).
Microglia counts, assessed by Iba1 at 5 and 20 weeks ( Fig. 1F-G; supplemental Fig. 1 ), decreased significantly with age ( Fig. 1H ) in Ctr cortex (p=0.049) and hippocampus (p=0.014), but remained elevated in 20 week old Tg mice. At five weeks, no statistical difference was observed in microglial count between Ctr and Tg mice; however, by 20 weeks, this difference was significant in both cortex and hippocampus (Fig. 1H) . Lonafarnib-treated 20-week old Tg mice (Fig. 2I-L) had a significant reduction in hippocampal microgliosis (Fig. 2M ) compared to age matched Unt transgenic mice.
Cortical astrogliosis was observed in transgenic mice as increased GFAP immunoreactivity ( Fig. 1A; red) , apparent from ~12 weeks and preceding the appearance of MC1 + neurons (supplemental Fig. 1 ). As transgenic mice aged, anti-GFAP immunoreactivity increased significantly in cortex, but not in hippocampus (Fig. 1I-K) . Lonafarnib treatment did not consistently affect astrocytic labeling (Fig. 2N -R) possibly due to its early onset that preceded the onset of microgliosis and tau inclusions.
Next we examined the effects of lonafarnib treatment upon sumoylation and ubiquitination in rTg4510 mice. These protein modifications are prominent features of the pathology (34, 36) .
Lonafarnib administration significantly altered the number of cells with detectable sumoylation ( Fig.   2S ; p=4.67x10 -5 ) and ubiquitination ( Fig. 2U ; p=2.49x10 -3 ). Using the number of double and single labeled cells, Bayesian probabilities were computed for cells labeled by MC1 given that they were labeled with anti-sumo (Fig. 2T ) or anti-ubiquitin (Fig. 2V) , thus comparing how well tau pathology correlated with the presence of sumoylation or ubiquitination. rTg4510 mice have many cells positive for sumoylation or ubiquitination without MC1 immunoreactivity. Using MC1 immunoreactivity as a prior, most cells also labeled positive for sumoylation or ubiquitination (supplemental Fig. 2 ).
Treatments with lonafarnib significantly altered the Bayesian probabilities observed of MC1 + cells given sumoylation ( Fig. 2T ; p=2.71x10 -5 ) and ubiquitination ( Fig. 2V; p=0.016 ).
Attenuation of the behavioral abnormalities in rTg4510 mice by a farnesyl transferase inhibitor.
As transgenic mice age, they display progressive behavioral worsening that begins with impaired marble burial and nest shredding (26, 27) and by 30 weeks progresses to hyperexcitability, restlessness in response to human approach and obsessive circling. Using the same lonafarnib treatment protocol described elsewhere (25, 28) beginning at ten weeks of age we sought to reduce or prevent the behavioral deficits induced by tau pathology. Nest building was assessed at 20 weeks.
Wild-type littermates produced well-rounded nests (Fig. 3A) ; however untreated transgenic mice (Tg) displayed poor nest shredding, and in some instances left bedding material completely undisturbed (Fig. 3B) . Lonafarnib treatment rescued nest building (Fig. 3C, D) . At five weeks, littermate controls and transgenic mice produced nests with similar scores (Ctr 3.58±0.13; Tg 3.23±0.12, p=0.639).
While control mice nesting scores did not significantly change with time (p=0.840), transgenic mice scores declined (Fig. 3D) . On the other hand, the marble burial deficit was observable at five weeks in transgenic mice and it remained unaltered by age (Fig. 3E-G) . In contrast to nest building, the marble burial deficit (Fig. 3E, F) was not improved by the drug in the transgenic mice (Fig. 3H) . One possibility that may account for this difference was the very early emergence of the marble burial deficit before lonafarnib administration, whereas shredding behavior emerged later. Lonafarnib does not appear to reverse existing pathology or deficits but seems to act as a preventive measure.
Farnesyl transferase inhibition with lonafarnib enhanced lysosomal protein degradation.
To determine the mechanism of action of lonafarnib we focused on its previously suggested role in autophagy (29) . Using NIH3T3 mouse fibroblasts expressing the tandem reporter mCherry-GFP-LC3B (30) to monitor macroautophagy (supplemental Fig. 3 ), lonafarnib treatment resulted in a dosedependent increase in macroautophagy flux, as revealed by an overall increase in autophagic vacuoles (AV) mostly due to an increase in autolysosome (AUT) abundance. At lower concentrations, the number of autophagosomes (APG) remained unchanged, suggesting their accelerated clearance by lysosomes (Fig. 4A-C and supplemental Fig. 3A, B) . Similar results were reproduced in neuroblastoma N2a cells (supplemental Fig. 3C ). The stimulatory effect of lonafarnib acted preferentially on basal macroautophagy as inferred by the fact that addition of lonafarnib to cells in which macroautophagy was induced either by paraquat (PQ) or thapsigargin (TG) did not further increase macroautophagy flux (supplemental Fig. 3D ). To determine whether lonafarnib also stimulated other forms of autophagy and confirm that the observed increase in macroautophagy was not a consequence of a blockage in another degradation pathway, we used a photoswitchable reporter for chaperone-mediated autophagy (CMA) (KFERQ-PS-Dendra) (31) ( Fig. 4D ; supplemental Fig. 3E, F) , and KFERQ-split-Venus double reporter for endosomal autophagy (8, 32) (Fig. 4E ).
Lonafarnib stimulated both forms of selective autophagy with maximal effect in the lower concentration range. In the case of CMA, the stimulatory effect of lonafarnib was more pronounced on basal CMA, but a significant increase was still observed after inducing CMA with PQ or TG (supplemental Fig. 3E, F) . Inhibition of lysosomal proteolysis with NH4Cl and leupeptin in cells expressing the KFERQ-split-Venus reporter demonstrated that lonafarnib not only promoted more efficient delivery of substrate to late endosome/multivesicular bodies via endosomal microautophagy, but also stimulated efficient internalization and degradation in this compartment (Fig. 4E) . Importantly, lonafarnib, had no measurable effect on proteasome-dependent degradation monitored in the same cell type using a Degron-GFP reporter (33) (Fig. 4F) .
The overall effect in all types of autophagy suggested a direct effect of lonafarnib in endo/lysosomal compartments shared by all these autophagic pathways without influencing the proteasome. To assess this possibility, proteolysis of long-half-life proteins was evaluated after a long pulse (48 h) with 3 H-leucine. Indeed, lonafarnib increased proteolysis in a dose dependent manner (Fig. 4G) , an effect that was abolished in the presence of NH4Cl and leupeptin (Fig. 4H ). These data support that lonafarnib treatment results in an overall improvement of lysosomal function and the pathways that mediate delivery of cargo to this compartment.
Rhes inhibition can reduce Tau-related pathology.
We sought the relevant targets of farnesyl-transferase inhibition that could account for the ameliorative effects of lonafarnib on tau pathology. Ras family members are among the prominent substrates of farnesyl transferase and this modification is required for their correct localization at the inner surface of the plasma membrane and for their biological activity. Of particular interest is the Ras family member, Rhes, because it is prenylated by farnesyl transferase (12) , activates autophagy, and can modulate the aggregation state of mutant Htt by promoting its sumoylation, thereby reducing cell survival (16) . To demonstrate that the effect of lonafarnib on tau pathology in rTg4510 mice could in part be accounted for by the inhibition of Rhes farnesylation, we modulated Rhes levels directly. AAV vectors (overexpression or silencing) were injected into the right amygdala of 10 week-old rTg4510 mice. When analyzed at 20 weeks ( Fig. 5A-F) , Rhes silencing (Rhes-miR) markedly reduced the number of MC1 + neurons ( Fig. 5H ; ANOVA cortex p=1.87x10 -4 , hippocampus p=0.002), reduced microgliosis ( Fig. 5I ; ANOVA cortex p=9.51x10 -5 , hippocampus p=6.75x10 -4 ) and increased the coronal section area ( Fig. 5G ; ANOVA p=3.56x10 -4 ). Therefore, Rhes inhibition recapitulated the effects of lonafarnib. Rhes over-expression did not appear to worsen the pathology (Fig. 5G-J) .
We examined the effects of Rhes silencing sumoylation and ubiquitination (34) in rTg4510 mice. Previous reports indicate that Rhes sumoylates mHtt aggregates (35) and tau is subject to both sumoylation and ubiquitination (34, 36) . Rhes-miR significantly altered the fraction of cells positive for sumoylation ( Fig. 5K-M ; ANOVA p=7.73x10 -3 ) and but not for ubiquitination ( Fig. 5O-Q ; ANOVA p=0.186). Using the number of double and single labeled cells, Bayesian probabilities were computed for cells labeled by MC1 given that they were labeled with anti-sumo (Fig. 5N ) or anti-ubiquitin ( Fig. 5N ; ANOVA p=0.030) or ubiquitination ( Fig. 5R ; ANOVA p=2.7x10 -3 ).
Linking lonafarnib treatment to Rhes-mediated effects on tau.
To link Rhes-induced tau pathology to its farnesylation we cultured hippocampal primary mouse neurons for three weeks at which time Rhes was over-expressed. As expected, Rhes overexpression markedly increased PHF-1 immunoreactivity. Mouse primary cultured hippocampal neurons were transduced with AAV (serotype 2/5) expressing Rhes, a GTPase inactive Rhes mutant (Rhes N33S), or a miRNA to silence Rhes (Rhes-miR). Over-expression of both Rhes variants increased PHF-1 (Fig. 6A, B) . Because the Rhes GTPase mutant affected PHF-1 tau equally well as the wild type we turned our focus to Rhes as a substrate for prenylation by farnesyl transferase (37) which appears to affect its cytotoxicity in HD models (16) . The farnesyl transferase inhibitor, lonafarnib added to the culture media, prevented PHF-1 tau accumulation in the presence of Rhes over-expression in a dose dependent manner (Fig. 6C, D) .
We next sought to determine whether the profile of proteostasis stimulation observed for lonafarnib paralleled its effects on PHF-1 in the presence of Rhes over-expression. Hippocampal primary mouse neurons were cultured for three weeks, transduced to overexpress Rhes, in the presence of 250 nM lonafarnib, and then additionally treated with either NH4Cl/leupeptin that prevents lysosomal mediated proteolysis, or MG-132 a proteasome inhibitors. Indeed, as predicted, the proteasome inhibitor MG-132 had no effect on the reduction in the presence lonafarnib of the Rhes mediated PHF-1 accumulation, whereas lysosomal inhibition with NH4Cl and leupeptin was very effective in blocking lonafarnib action, as observed by the steadily accumulation of PHF1 immunoreactivity at 24 h (Fig. 6E, F) . p62 changes are shown as positive control as it is known to undergo degradation both by the proteasome and in lysosomes (Fig. 6G) .
Developmental control over Rhes expression is associated with a homeostatic response to tau.
Human induced pluripotent stem cell-derived (hiPSCs) neurons from frontotemporal mutation patients harboring either MAPT mutations (P301L (38) 
C9ORF72 expansion (42) or clinically healthy age-matched controls were analyzed by RNAseq ( , ZPF41=0.047, NEK9=0.348 n.s.). RASD2 levels in the tau mutants were confirmed in a set of isogenic controls. Real time RT-PCR in three independent sets of hiPSCs derived neurons with different MAPT mutations and their isogenic controls showed the expected DE RASD2 levels (MAPT-P301L/P301S (Fig. 7H) , MAPT-V337M (Fig. 7I ) and MAPT-R406W (Fig. 7J ). In agreement with the RNAseq, MAPT expression did not change significantly in any of isogenic controls ( Fig. 7K-M) . Curiously, however, the direction of change in RASD2 was decreased in the tau mutants relative to the controls.
To understand the context of RASD2 level regulation we next found that RASD2 expression levels in a control line increased during iPSCs differentiation; however, in MAPT-P301L and MAPT-V337M lines RASD2 levels remained low throughout differentiation ( ) and hippocampus (ANOVA p=0.014).
Discussion
Attempts to treat the tauopathies, particularly those individuals with tau mutations, has been impeded by the absence of an understanding of the molecular pathways that connect genotype to phenotype. The remarkable effects of the farnesyl transferase inhibitor, lonafarnib, on tau pathology allowed the use of this drug as a probe for the discovery of disease-relevant pathways. Although farnesyl transferase inhibitors, such as lonafarnib, will affect many farnesylated substrates, the major effects of the drug appear to be mediated through membrane associated Rhes and therefore points to a regulated pathway as a druggable target. Lonafarnib has its principal effect on enhancing protein degradation in the lysosome (Fig. 4) . When Rhes was over-expressed in neurons to increase PHF-1 and then treated with lonafarnib to reduce PHF-1, the effects of the drug were prevented by the lysosomal inhibitors, NH4Cl and leupeptin ( Fig. 6E-G) . Furthermore, inhibition of Rhes in the rTg4510 mouse phenocopied the effects of lonafarnib (Fig. 5 ). Positing the lysosome as the drug target in the mouse is consistent with observations that the P301L mutation interferes with the degradation of tau through all the autophagic pathways (8).
Many questions remain regarding the pathway from membrane disassociation of Rhes to lysosomal activation (supplemental Fig. 5 ). Farnesylation of Rhes may serve as a switch between its effect on mTOR to inhibit autophagy and on beclin-Bcl2 to activate autophagy. The regulation of autophagy by Rhes under neurodegenerative disease conditions was reported to be independent of mTOR (15) , and as such, strategies that activate mTOR may not be opportune therapeutic options.
On the other hand, strategies that activate autophagy have shown beneficial effects (44, 45) .
Contributing to the mechanism of Rhes is its role as a sumo ligase (16) . Tau is both sumoylated (34) and ubiquitinated (36, 46) . Although a direct interaction between Rhes and tau has not yet been demonstrated, mutant Huntingtin can bind to Rhes (16) .
Sumoylation can become activated under certain stress conditions. An increase in Sumo conjugation has been observed, for example, upon heat shock, osmotic stress and hibernation (47) (48) (49) . Both Rhes-miR and lonafarnib were able to suppress sumoylation and ubiquitination in rTg4510 mice ( (Fig. 2T, V) and Rhes-miR (Fig. 5N, R) decreased the probabilities of double-labeling, thereby suggesting a link between the Rhes pathway and activation of sumoylation and/or ubiquitination.
From stem cells (50) to aged cells (51) proteostasis is a highly regulated process over the lifespan. Indeed, Rhes levels are developmentally regulated with low levels in neuronal precursors and young animals that gradually increase with maturation (Fig. 8) . The persistently low levels of Rhes in tau mutation harboring iPSC-derived neurons (Fig. 7) suggested a homeostatic response to the mutation (15, 52) by which the cell can sense tau mutations before inclusions are evident and respond by activating the lysosome through endogenous reduction of Rhes. In fact, an increase in lysosomal proteolysis in response to mutant tau expression has been reported (8) . Immature hiPSCderived neurons and young rTg4510 mice appear to compensate for the deleterious effects of the tau mutation by reducing Rhes levels (Figs. 7B, E, H-J, and 8C). Under control conditions RASD2 (the Rhes transcript) expression rises coincident with increases in tau levels; whereas, this rise in Rhes fails to occur in the presence of tau mutations ( Fig. 8A-B) . Tracking Rhes levels in hiPSC-derived neurons is limited by the fact that these cells do not fully mature. However, the advancing tau pathology in rTg4510 mice, appeared to escape auto-regulatory controls and Rhes levels do rise (Fig.   8C ). This Rhes sensor system appears sufficiently sensitive to detect the tau P301L mutation in the alternatively spliced tau exon 10, which is expressed, albeit at low protein and mRNA levels in hiPSCderived neurons (unpublished observations). A similarly complex picture regarding the role of Rhes in HD has been proposed (15) . Rhes is down-regulated in HD (53, 54 ) and yet increasing Rhes expression augments cytotoxicity (38) . Thus the Rhes pathway serves as a highly sensitive sensor.
This Rhes lowering strategy was adopted pharmacologically in older animals to treat the tauopathy.
By inhibiting Rhes farnesylation its levels are reduced probably due to its degradation when free in the cytoplasm.
The pharmacological approach described here will likely require early and chronic intervention.
Indeed, once pathology emerged lonafarnib was no longer effective. Impairment in marble burial, which emerged before 10 weeks when the drug was delivered and well-before tau inclusions were observed could not be remediated. Nevertheless, the broad implication of proteostasis in many neurodegenerative diseases including Parkinson's disease, Huntington's disease, Alzheimer's disease, and other types of frontotemporal dementia (51, 55, 56) requires a concerted effort to explore relevant pathways for therapeutic effects. The safety profile of lonafarnib (19, 20) and its efficient crossing of the blood brain barrier (19) , makes this drug a promising candidate for repurposing to treat tauopathies due to tau mutations.
Materials and methods
Animal maintenance and treatments.
This study was conducted in accordance with the National Institute of Health Guide for the Care and 
Behavioral characterization.
Nest shredding behavior was qualitatively measured according to published guidelines (27) with modifications. Briefly, unscented nestlets were provided during husbandry and kept in the cage for 24 h. Nest shredding behavior overnight was estimated on a 0-5 scale with zero indicating unshredded bedding material while a five denoted a completely shredded nest that displayed a rounded appearance. Twenty-five blinded independent observers reviewed images of overnight nests and the average quality scores were calculated. Following this time, a picture of the remaining nestlet or the nest was taken and the pictures scored on a 0 to 5 scale: 0 for an un-shredded nest, 1 and 2 for nests slightly to moderately shredded, 3 and 4 for nests that were shredded but the appearance of the nest was flat, and 5 for nests that were fully shredded and the appearance of the nest was round and full.
Scores of each nest were assigned blindly by 25 independent observers, and these scores were averaged to produce net-scores (Fig 3D) . One-way ANOVA tests followed by Tukey post-hoc test were used to determine statistical significance in the difference of means.
Marble burial was evaluated as previously reported (26) with minor modifications as follows: 20 marbles of 15 mm in diameter were spaced by 4 cm in five rows of four marbles each, on the surface of a gently packed 5 cm deep wood chip bedding in a double-size rat cage. A mouse was left alone in the cage for 30 min and then returned to its housing cage. The number of marbles buried was counted by an observer blinded to the treatment. Any marble buried more than 2/3 of its size was counted. Each mouse was assessed three times on consecutive days, at the same time in the afternoon, and data reported as average ± s.e.m. of the percentage of buried marbles per animal.
One-way or two-way ANOVA tests followed by Tukey post-hoc where applicable were used to determine statistical significance.
Evaluation of intracellular proteolysis and autophagy in lonafarnib treated cells.
Mouse fibroblasts (NIH3T3) or neuroblastoma N2a cells were obtained from the American Type
Culture Collection (ATCC). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO) in the presence of 10% newborn calf serum (NCS), 50 μg/ml penicillin and 50 μg/ml streptomycin at 37°C with 5% CO2, and treated with varying concentrations of lonafarnib (0.25-1 μM).
Macroautophagy activity in intact cells was measured upon transduction with lentivirus carrying the mCherry-GFP-LC3 tandem construct (30).
Cells were plated on coverslips or glass-bottom 96-well plates and fluorescence was read in both channels. Puncta positive for both fluorophores correspond to autophagosomes whereas those only positive for the red fluorophore correspond to autolysosomes. Autophagic flux was determined as the conversion of autophagosomes (yellow) to autolysosomes (puncta; red).
Chaperone-mediated autophagy (CMA) activity was quantified in intact cells using the photoswtichable (PS) KFERQ-PS-Dendra2 reporter transduced into cells using lentiviral delivery (31).
Cells were photoswitched with a 405 nm emitting diode (LED: Norlux) for 4 min with the intensity of 3.5 mA (current constant). CMA activity was quantified as number of Dendra photoconverted positive puncta per cell.
Endosomal microautophagy (32) activity was measured in intact cells using a recently developed KFERQ-N-terminus Split Venus and the KFERQ-C-terminus split Venus (8) . As the half proteins are targeted to the multivesicular bodies in late endosomes, the confined space inside these vesicles favors the interaction of the two parts, and once Venus is joined punctate fluorescence results. The amount of reporter undergoing degradation in this compartment can be estimated by comparing number of puncta in cells treated or not with NH4Cl and leupeptine to inhibit lumenal degradation.
To determine possible changes in proteasome-dependent degradation, cells were transduced with lentivirus carrying the degron-GFP (33) that will undergo rapid degradation inside cells unless lactacystin is added to inhibit proteasome activity. Rates of degradation are calculated as the increase in total cellular fluorescence upon addition of lactacystin, and discounting changes in cells transduced with lentivirus carrying a mutant-degron-GFP, unable to undergo selective proteasome degradation.
For all reporters, cells plated in glass-bottom 96-well plates were treated for the indicated times and after fixation images were acquired using a high-content microscope (Operetta, Perkin Elmer).
Images of 9 different fields per well were captured, resulting in an average of 2,500-3,000 cells.
Nuclei and puncta were identified using the manufacturer's software. The number of particles/puncta per cell was quantified using the "particle identifier" function in the cytosolic region after thresholding in non-saturated images (67) . In all cases, focal plane thickness was set at 0.17 μm and sections with maximal nucleus diameter were selected for quantification. Values are presented as number of puncta per cell section that in our acquisition conditions represents 10-20% of the total puncta per cell.
To measure degradation of long-lived proteins, confluent cells were labeled with 3 H-leucine (2 μCi/ml) for 48 h at 37°C, and then extensively washed and maintained in complete (10% NCS) or serum-deprived media containing an excess of unlabeled leucine (2.8 mM) to prevent reutilization of radiolabeled leucine (68) . Aliquots of the media taken at different times were precipitated with TCA and proteolysis was measured as the percentage of the initial acid-insoluble radioactivity (protein) transformed into acid-soluble radioactivity (amino acids and small peptides) at the end of the incubation. Total radioactivity incorporated into cellular proteins was determined as the amount of acid-precipitable radioactivity in labeled cells immediately after washing.
All numerical results are reported as mean + s.e.m. Statistical significance of the difference between experimental groups was analyzed by two-tailed unpaired Student's t-test. Differences were considered statistically significant for p<0.05.
Evaluation of proteolysis contribution on lonafarnib enhanced tau degradation.
Hippocampal primary mouse neuronal co-cultures were prepared from E19 mouse hippocampi, reprogrammed from skin biopsy fibroblasts from three independent clinically healthy controls (CTR2, CTR3, and F11349.2), and four independent fronto-temporal mutation patients carrying different MAPT mutations (P301L, G55R, V33M, or R406), and a disease control, C9ORF72 (supplemental Table 1 were not added to the media for the cell culture studies.
Isogenic iPSC and neuronal differentiation.
iPSCs carrying MAPT-P301L (F05010), MAPT-V337M (ND32591A), and MAPT-R406W (F11362) mutations were differentiated to neurons. Isogenic lines were generated in a footprint-free, seamless manner (i.e. no blocking mutations) using CRISPR/Cas9. Sanger sequencing was performed to confirm clones were correctly edited at on-target sites and free of indels or modifications at predicted off-target sites. All clones were confirmed to have normal karyotype after editing. Isogenic pairs were differentiated into neurons using a two-step protocol. Briefly, iPSCs were plated in neural induction media (StemCell Technologies) in a 96-well v-bottom plate to form highly uniform neural aggregates and after five days transferred onto culture plates. The resulting neural rosettes were then isolated by enzymatic selection. The NPCs are differentiated in planar culture in neural maturation medium (neurobasal medium supplemented with B27, GDNF, BDNF, cAMP) for six weeks mRNA Transcript quantification.
Genome-wide poly-A RNA transcripts were quantified using five-week-old neuronal cultures differentiated from patient and control hiPSCs as described above. RNA sequence was obtained from three independent hiPSC neuronal differentiation events from each individual. Total RNA was collected from a total of four six-well plates of neurons grown at a density of 2x10 Principal component analyses were performed using normalized CPMs for all post-filtered genes (supplemental Fig. 4A,B) and for genes identified as DE (supplemental Fig. 4C ). Cartesian representations for PC1 vs PC2 captured most of the variability as additional principal components represented less than 10% of the expression variability in all cases (supplemental Fig. 4A ).
Expression of MAPT and RASD2 were quantified from total RNA (miRvana kit) at day 0 (hiPSCs), day 6 (embryoid bodies), day 12 (neurorossetes), and day 20 (neurospheres) with quantitative PCR using taqman primers specified above. Data was calculated as 2 -ΔCt for changes in gene expression level compared to hiPSCs stage. Two-way ANOVA test followed by Tukey HSD post-hoc tests where applicable were used to test differences in means across different cells lines along differentiation stages. Tukey-HSD test at *p<0.05, **p<0.01, ***p<1x10 -3 . Scale bar 100 μm. Rhes levels increase as mice age in both transgenic and control mice, these are significantly lower in younger transgenic mice (N=3; two-way ANOVA, age p=3.24x10 -3 ; genotype p=8.01x10 
